To date, several promising predictors of ABC efficacy or resistance in breast cancer have been proposed and assessed, such as GR, NUP98, FKBP12, and ERCC,28, 29, 30, 31 to guide the selection of the appropriate treatment and maximize the benefit of chemotherapy for patients, avoiding unnecessary adverse events, costs, and risk of progression. Here, FKBP1A is linked to breast cancer.